<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04895657</url>
  </required_header>
  <id_info>
    <org_study_id>198</org_study_id>
    <nct_id>NCT04895657</nct_id>
  </id_info>
  <brief_title>Extended-infusion of Piperacillin-Tazobactam Versus Intermittent Infusion</brief_title>
  <official_title>Extended-infusion Piperacillin-Tazobactam Versus Intermittent-Infusion Dosing Strategy in Critically Ill Patients With Suspected or Confirmed Bacterial Infections.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Continuous-infusion of piperacillin/tazobactam over 4 hrs instead of 30-minute intermittent&#xD;
      dosage regimen has shown observable outcomes. Our objective is to assess whether continuous&#xD;
      infusion of piperacillin/tazobactam is superior in terms of efficacy, safety and cost to the&#xD;
      intermittent regimen to treat suspected or proved infections due to gram negative bacteria.&#xD;
      The setting is Critical Care Medicine Department at Cairo University Hospitals. Methods A&#xD;
      prospective randomized comparative study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 56 patients were recruited from ICU- Cairo University Hospitals. All adult&#xD;
      critically ill patients admitted to Critical Care Medicine Department with suspected or&#xD;
      confirmed bacterial infections on admission or during their ICU stay were assessed for&#xD;
      inclusion into the study. All patients were subjected to the following: A. Patient's full&#xD;
      history: Age, sex ,medical history ,concurrent diseases, concurrent medications&#xD;
&#xD;
      B. Patient evaluation and assessment:&#xD;
&#xD;
      The following were evaluated at baseline and periodically thereafter until day of stopping&#xD;
      antibiotic, discharge and/or death :&#xD;
&#xD;
        1. Kidney functions (Serum creatinine, blood urea nitrogen)&#xD;
&#xD;
        2. Liver functions (ALT, AST, Bil D, Bil T, Albumin)&#xD;
&#xD;
        3. Complete blood count&#xD;
&#xD;
        4. Microbiological Evaluation: Cultures and sensitivity tests from suspected site of&#xD;
           infection&#xD;
&#xD;
        5. Clinical signs and symptoms of infection documented by the attending physician on&#xD;
           patient's medical record&#xD;
&#xD;
        6. APACHE II Variables&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 27, 2018</start_date>
  <completion_date type="Actual">January 26, 2020</completion_date>
  <primary_completion_date type="Actual">January 26, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical cure</measure>
    <time_frame>ICU length of stay, assessed up to 30 days</time_frame>
    <description>Clinical cure, expressed in percentage, will be considered fulfilled if all the following criteria are met : Cure or improvement of clinical signs and symptoms caused by the infection, normalized WBCs and body temperature.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total cost</measure>
    <time_frame>ICU length of stay, assessed up to 30 days</time_frame>
    <description>Cost in Dollars (prices of drugs ,supplies prices, preparation, administration, daily hospital stay cost )</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ICU Length of stay</measure>
    <time_frame>ICU length of stay, assessed up to 30 days</time_frame>
    <description>ICU Length of stay in Days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>ICU length of stay, assessed up to 30 days</time_frame>
    <description>percentage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readmission within 30- days</measure>
    <time_frame>30 days</time_frame>
    <description>Days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse drug events</measure>
    <time_frame>ICU length of stay, assessed up to 30 days</time_frame>
    <description>Any adverse event occurring during study drug administration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Gram-Negative Infections</condition>
  <arm_group>
    <arm_group_label>Piperacillin/Tazobactam Intermittent infusion</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>4.5 gm Piperacillin/Tazobactam I.V intermittent over 30 min. every 8 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Piperacillin/Tazobactam Continuous infusion</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>4.5 gm Piperacillin/Tazobactam I.V extended infusion over 4 hours every 8 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Piperacillin/Tazobactam Continuous infusion</intervention_name>
    <description>Continuous infusion</description>
    <arm_group_label>Piperacillin/Tazobactam Continuous infusion</arm_group_label>
    <other_name>Piprataz injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Piperacillin/Tazobactam Intermittent infusion</intervention_name>
    <description>Intermittent infusion</description>
    <arm_group_label>Piperacillin/Tazobactam Intermittent infusion</arm_group_label>
    <other_name>Piprataz injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults aged 18-74 years&#xD;
&#xD;
          -  Expected ICU stay more than 24 hours&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergy or potential allergy to the study medications&#xD;
&#xD;
               -  Pregnancy&#xD;
&#xD;
               -  Patients with CrCl&lt; 20 ml/min or on dialysis&#xD;
&#xD;
               -  Cancer patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cairo University Hospitals</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 19, 2021</study_first_submitted>
  <study_first_submitted_qc>May 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2021</study_first_posted>
  <last_update_submitted>May 18, 2021</last_update_submitted>
  <last_update_submitted_qc>May 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Christina Medhat</investigator_full_name>
    <investigator_title>Teaching assistant</investigator_title>
  </responsible_party>
  <keyword>Antibiotics</keyword>
  <keyword>Beta-lactams</keyword>
  <keyword>Continuous administration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Piperacillin</mesh_term>
    <mesh_term>Piperacillin, Tazobactam Drug Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 24, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/57/NCT04895657/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

